AllianceBernstein’s Cartesian Therapeutics RNAC Stock Holding History

AllianceBernstein’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92K	Hold	12,765	–	–	﹤0.01%	3164
2025 Q4	$92K	Hold	12,765	–	–	﹤0.01%	3177
2025 Q3	$130K	Buy	12,765 +870	+7%	+$9.78K	﹤0.01%	3151
2025 Q2	$124K	Buy	+11,895	New	+$127K	﹤0.01%	3141
2024 Q2	–	Sell	-576	Closed	-$11.2K	–	3288
2024 Q1	$11.2K	Hold	576	–	–	﹤0.01%	3132
2023 Q4	$11.9K	Hold	576	–	–	﹤0.01%	3175
2023 Q3	$18.3K	Sell	576 -181	-24%	-$6.05K	﹤0.01%	3173
2023 Q2	$25.4K	Buy	+757	New	+$27.1K	﹤0.01%	3151
2022 Q2	–	Sell	-3,690	Closed	-$136K	–	3359
2022 Q1	$136K	Buy	3,690 +10	+0.3%	+$626	﹤0.01%	3073
2021 Q4	$360K	Hold	3,680	–	–	﹤0.01%	2880
2021 Q3	$459K	Hold	3,680	–	–	﹤0.01%	2788
2021 Q2	$461K	Buy	3,680 +947	+35%	+$113K	﹤0.01%	2841
2021 Q1	$371K	Sell	2,733 -550	-17%	-$68.3K	﹤0.01%	2816
2020 Q4	$298K	Sell	3,283 -1,680	-34%	-$146K	﹤0.01%	2853
2020 Q3	$369K	Sell	4,963 -827	-14%	-$63.4K	﹤0.01%	2697
2020 Q2	$493K	Buy	+5,790	New	+$525K	﹤0.01%	2624

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's RNAC Position: Q1 2026 in Review

AllianceBernstein held its Cartesian Therapeutics (RNAC) position steady in Q1 2026 at 12,765 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #3164.

AllianceBernstein first reported a position in RNAC in Q2 2020 and has held it in 16 quarters since. The position peaked at $493K in Q2 2020. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

AllianceBernstein held 12,765 shares of Cartesian Therapeutics worth $92K as of Q1 2026.
AllianceBernstein left its Cartesian Therapeutics share count unchanged in Q1 2026.
Cartesian Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #3164 holding.
AllianceBernstein first reported a position in Cartesian Therapeutics in Q2 2020 and has held it in 16 quarters since.
AllianceBernstein's Cartesian Therapeutics position peaked at $493K in Q2 2020.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.